Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Announces Preliminary 2025 U.S. Net Sales of $105M for TRYNGOLZA
Summary
Ionis Pharmaceuticals, Inc. reported preliminary U.S. net product sales of $105 million for TRYNGOLZA in 2025. The company also announced additional updates and milestones expected in 2026, including potential launches of breakthrough therapies and pivotal data readouts. The unaudited results are provided as an approximation in advance of the Company's announcement of complete financial results in February 2026.
Profitelligence Alerts
Get alerts for IONS
Be first to know when Ionis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Official SEC Documents
Advertisement